ACT Genomics is a leading supplier of precision oncology solutions with over 200 partnerships with hospitals in the Asia region. We keep abreast of the latest in biomarker discovery in clinical trials. This allows us to provide a broad spectrum of cutting-edge solutions to optimize the treatment of cancer through our validated tests for biomarker exploration, patient stratification, and patient referral program. The data analysis is conducted at our CAP-accredited laboratories based in Taiwan, Hong Kong, or Japan. In addition, the proprietary pipelines in bioinformatics and medical interpretation enable us to generate precious molecular information across all solid tumor types at all stages of disease.
With our active participation in various international precision oncology programs, ACT Genomics is committed to be a major contributor to precision medicine by working with pharmaceutical companies to accelerate clinical trials through retrospective analysis, patient screening, precision patient enrollment and companion diagnostic development.